Friday, July 10, 2026

biotech · Glioblastoma · Recurrent Brain Metastases · GTBP

GT Biopharma

GT Biopharma is a biotech organization headquartered in Brisbane, USA. It trades on NYSE under ticker GTBP. Primary therapeutic focus areas include Glioblastoma, Recurrent Brain Metastases, High-risk Myelodysplastic Synd

Brisbane, USA HQ
1973 Founded
8 Employees
Public company Type
GTBP · NYSE Ticker
Company details
Status
Public
HQ
Brisbane, USA
Founded
1973
Employees
8
Programs
8
Drugs
7
Patents
1
Clinical program

Stereotactic Radiation Therapy

Phase 3 · other · Brain Metastases

Stereotactic Radiation Therapy for Brain Metastases is a Phase 3 program (other) at GT Biopharma with 1 ClinicalTrials.gov record(s).

← All GT Biopharma projects Phase 3 other active

Internal code GTM-102

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
GT Biopharma
Phase
Phase 3
Modality
other
Indication
Brain Metastases
Status
active
Trials
1